Saturday, November 16, 2024

HealthTech Report: The ALFASIGHT 9000


INTRODUCTION: In our constant search for the latest innovations in non‐invasive health and medical advancements, HealthTech Reporter met with DR. DANIEL BEILIN of Alfa Thermodiagnostics, the developer of the ALFASIGHT 9000. 

In August of 2024, HealthTech Reporter conducted a private interview with Dr. Daniel Beilin (CTO  & Founder) about establishing the science of Regulation Thermography and his ALFA System.

TECH DESCRIPTION FROM THE WEBSITE: 
The AlfaSight 9000™ (also known as the ALFA‐Scan System) is a robust, easy‐to use, and reproducible measurement system that utilizes streamlined infrared technology, artificial intelligence (AI) ‐ and years of world‐corroborated, accumulated data. It’s a whole‐body, early‐detection system that views a patient’s overall health while finding hidden issues and causes for many disease including pre‐disease contributing factors.

According to the manufacturer, this adjunct diagnostic device may detect the following Organ Dysfunctions:

‐ Diabetes and Pre‐Diabetes (Pancreas)
‐ Breast (Breast Health, DCIS and Cystic Changes)
‐ Vascular Brain and Headache Origins
‐ Liver Disorders and Disease
‐ Endocrine Function (Pituitary/Thyroid/Ovary)
‐ Cardiac Function (Efficiency, Electrophysiology)
‐ Early or Hidden Dental Infections
‐ Structural Integrity (Neuromuscular)
‐ Pulmonary Function
‐ Viral and Bacterial Disease Monitoring
‐ Kidney Dysfunction
‐ Lymphatic Monitoring




FROM DR. BEILIN'S INTERVIEW
Dr. Daniel Beilin is an American specialist in alternative medicine for over 35 years. He has a neurophysiology, gastroenterology, and herbal sciences background. His first research at the age of 16 included his own laboratory at the UCLA Brain Research Institute and is now internationally recognized for his contributions to detection of the causes of cancer and immune dysfunction with cutting‐edge precision‐based European diagnostic tools

PHILOSOPHIES: I was six and a half years in academic medical research when I decided that conventional medicine as it is practiced relies on quick recipe formulas that all too‐often disregard the individual case and differences of the constitutional strengths and weaknesses of patients. Whereas (truth is), every individual is different; the same pneumonia patient can have a different etiology and a different organ involvement that helps to make the person vulnerable to not only pulmonary disease, but lays a susceptibility to other diseases including cancers or autoimmune disorders.

I wanted to explore the terrain, which means that our own physiological functions affected by the
autonomic nervous system, our metabolism, environmental toxic exposures, our diet‐‐ all of these factors are usually ignored by conventional medicine. When someone walks in a clinic with a particular disease, physicians all too often target the end stage symptom and rarely identify CAUSE, thereby never addressing long term prevention. They can save lives as surgeons can definitely do a good job of that, but then what? In the search for a preventive world, there must be an understanding of how to see things that are originally invisible, diseases that are developing, ‐and not yet causing tissue damage or advancing pathology, as would be seeable in a blood test.

Alfa’s technology vaguely overlaps acupuncture, Ayurvedic and Chinese medicine, however traditional medicine needs more objective and reproducible diagnostics that can finally be gained by the sensitivity and specificity of Regulation Thermometry. It's more in line with neurology. The doctors that can immediately understand what we're doing by our device are nuclear medicine physicians and cardiologists... because what we're really doing is a process of challenging the body and examining the responses to the challenge. We do this simply by subjecting the patient to the cooler air of a normal room, before and after clothing removal. By this dynamic temperature analysis, we can understand health, like opening up a new visual method of invisible causes that explain many disease processes from their beginnings. We are finally able to see the resilience characteristics expressed through each organ system by simple stress-analysis. From here, we take a 'before and after' exposure measurements, then we're able to define where in the body are the non‐ideal atypical responses, then corroborate with directed, specific laboratory tests or imaging diagnostics.

MY HISTORICAL PATH OF THE ALFASIGHT 9000: 
I started this path by visiting clinics and laboratories in Germany in 1979. Over the next 40 years, I attended in different integrative medicine clinics and hospitals in Europe. As you may know, Germany has always combined conventional medicine with alternative methods such as homeopathic medicine, herbal medicine and nutritional medicine. The Europeans are the most open‐minded alongside being science-based, and of course, very ‘logical’ in the way they think (over 50% of physicians in Germany utilize some form of unconventional medicine such as acupuncture, nutrition or physical therapeutic methods.


ALFA'S SYSTEM ORIGINS…
There was a Dr. Schwamm who invented this method of neurologically‐based regulation analysis. I explored his work through his students (since he had died by the time I got there). One of them was a Dr. Reimar Banis who was an internist who partnered with a gynecologist, told me about this great diagnostic tool. They had discovered hidden factors in their scans that proved to lead to breast and cervical cancers.

To clarify,  I did not invent the technology, but I led a team and improved the hardware (and software) it vastly to be more stable and accurate. We identified patterns of disease-complexes by repeated testing of hypothetical variants which led to establishing formulas or algorithms (pattern recognition). The values that we now acquire are more highly calibrated to detect disturbances in signaling from physiological systems and make them even more recognizable. Banis came to me and said, "I know the guy that is manufacturing the devices, so why don't you see if you can get it through the FDA, and then you could distribute them and then educate doctors." So that's exactly what I did.

I brought this original device to FDA, cleared it with the Department of Radiological Devices and distributed them to over 120 clinics in North America. I then improved the device and got the second one cleared with FDA. We began a new introduction to the device in leading integrative medicine conferences, as it clearly gives a new vision to the causes of many disorders and syndromes.  We were then endorsed by physicians who are leaders in the field of complementary medicine.


MORE DETAILS ON WHAT IT DOES
This method of measuring skin temperatures before and after a stress by temperature change, isn’t trying to look INSIDE the body like an X-Ray or MRI, but instead it is taking the skin's temperature within organ‐’reflection’ zones, -as the skin is controlled by the sympathetic nerves that control capillaries to open and close, letting heat out or keeping heat in. In fact, we're using the sympathetic nervous system by way of connections through the spinal REFLEX ARC, connecting with the internal organs carrying projected information from specific organ systems as well as tissues such as breasts, lymph and through pattern-recognition, identifies many more syndromes as well as neurological problems.

THE PATIENT EXPERIENCE
It's a single 20‐minute test. It involves taking the first measurement from the head down to just below the waist, and then removing clothes to the underwear, so that the patient then becomes exposed to the cooler room-air for 10 minutes. This initiates a fight or flight reaction whereby the blood shunts to your core and to your head. The response is quantified according to known patterns that have been corroborated with laboratory tests and imaging over the last 45 years (Europe originally). 

By looking at the responses, before and after cooling, in approximately a hundred points, we're able to obtain information about organ systems that may be abnormally functioning those that are in their infancy stage up to their actual disease state. This opens up a whole new window for true, preventive care.

Five years ago, I presented at Beth Deaconess Hospital in Boston (Harvard) to 10 radiologists. One of them was the lead expert who leads all breast cancer radiological research, trying to use computer assisted diagnostics (CAD) and applying artificial intelligence to mammograms. She told me at the time that their computer assisted diagnosis was a near‐ complete failure and that the radiologist's eyes are still the most accurate assessment tool.

This uses up a lot of hours and manpower and very highly trained, trained people. She liked the Alfa system because it, as she said, “digitizes, making results objective”, and “it looks like you have algorithms that may depict developing breast cancers, which is what we are looking for in our research."

We planned a study on breast assessment in two categories. Ones that are not yet known, whether they're producing a neoplasm (cancer tumor) yet, and known breast cancers that have been treated, in order to better establish categories of patterns depicting recurrence probability. 

Within this time, the FDA cleared our 510k and declared our device, the AlfaSight 9000 system as an ADJUNCT diagnostic system. This means that it doesn't tell you that you have cancer; if you have hepatitis (per‐se), but instead, it tells you that "you better do some imaging in this area‐‐ or perhaps you ought to go out for a blood test here because we have the pattern of, say, autoimmune thyroid like Hashimoto's or Graves disease" but need to confirm in specific, cost‐effective ways.

This kind of information gathered by this dynamic, functional physiological analysis approach assists doctors in making better decisions on what to test for and ways to individualize protocol treatment strategies. The Alfa system has a very high specificity for about 35 conditions. The test takes 20 minutes and certified technicians can be taught how to operate it in an hour‐ which includes generating a report based on all the data that's accumulated for proper interpretation and strategy-planning.

To date, we have 180 devices in 14 countries right now. Planned is a new project with the now-largest hospital in Asia (AIMS Hospital, just outside Delhi with the lead physician, Dr. Prem Nair. We are advancing into projects with our device that may lead to a crucial step: functional physiological resilience analysis. 

Patients improve faster and more completely if they are systemically resilient, now there is a method to measure that resilience.  My hope and clear goal is to maximize that possibility with this reproducible data-driven comprehensive measurement tool. 

Contact: https://alfathermo.com 
info@alfathermo.com 
drbeilin@alfathermo.com  
tel: (831) 708‐2212




























No comments:

Post a Comment

HealthTech Report: The ALFASIGHT 9000

INTRODUCTION: In our constant search for the latest innovations in non‐invasive health and medical advancements, HealthTech Reporter met wit...